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population is likely to increase the incidence of aortic
valve disease and the demand for AVR in the future.
Although patient preference and the risk of anticoagula-
tion with warfarin sodium are often considered in select-
Objectives: This study was designed to determine the effects of age, coro-
nary artery disease and other cardiac comorbidities on late outcome fol-
lowing bioprosthetic aortic valve replacement. Methods: Data were
prospectively collected on 670 patients undergoing aortic valve replace-
ment with the Hancock II bioprosthesis (Medtronic, Inc, Minneapolis,
Minn) between 1982 and 1994. Mean patient age was 65 ± 12 years
(median, 68 years; range, 18-86 years). Follow-up was 99.7% complete
at 69 ± 40 months (median, 66 months; range, 0.1-168 months). Survival
and freedom from reoperation were evaluated univariately by Kaplan-
Meier analysis and multivariably by Cox regression. Results: After
adjustment for gender, Cox regression analysis revealed that age of 65
years or older, left ventricular dysfunction, the presence of coronary
artery disease, and advanced New York Heart Association functional
classification were associated with a higher risk of late death. At 12
years, survival was significantly different by Kaplan-Meier analysis for
both age younger than 65 years (71% ± 4%) versus age 65 years or older
(36% ± 7%; P < .0001), left ventricular function grades 3 and 4 (26% ±
13%) versus grades 1 and 2 (59% ± 4%; P < .0001), no coronary artery
disease (65% ± 4%) versus coronary artery disease (35% ± 8%; P <
.0001), and functional class IV (33% ± 9%) versus classes I to III (62%
± 4%; P < .0001). Only 9 patients experienced primary tissue failure, all
of whom were younger than 65 years of age. At 12 years, the freedom
from primary tissue failure was 84% ± 4% for those patients younger
than 65 years of age, and 100% for those 65 years of age or older (P =
.006). Conclusions: Long-term survival after aortic valve replacement is
highly dependent on age, coronary artery disease, functional class, and
left ventricular function, although bioprosthetic durability is dependent
almost solely on age. Due to increased valve durability in patients who
are 65 years of age or older, the Hancock II bioprosthesis may be an ideal
aortic valve substitute in this age group. In patients who are younger
than 65 years of age with advanced functional class, impaired left ven-
tricular function, and coronary artery disease, this valve may also be
used with a low probability of primary tissue failure. Patients without
additional cardiac comorbidity may outlive their bioprosthetic valve,
leading to reoperation. (J Thorac Cardiovasc Surg 1999;117:273-84)
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A ortic valve replacement (AVR) is the treatment ofchoice for advanced aortic valve disease and cur-
rently accounts for 13% of all adult cardiac surgery in
Ontario.1 Prolonged life span in a progressively aging
ing the most appropriate valvular prosthesis (tissue vs
mechanical), predictors of survival are often over-
looked. Matching patient survival to prosthetic durabil-
ity is crucial in view of the increased morbidity and
mortality rates associated with reoperative valvular pro-
cedures.2 Moreover, appropriate allocation of patients to
a specific valve type may reduce valve-related compli-
cations and allow for improved quality of life.
Advanced age and concomitant coronary artery dis-
ease (CAD) have long been described as independent
predictors of both early and late morbidity and death
after AVR.3-7 This study defines both the independent
and combined effects of these and other cardiac comor-
bid factors on long-term patient survival after biopros-
thetic AVR.
Methods
Patients. Between September 1982 and December 1994 at
The Toronto Hospital, 670 consecutive patients underwent
isolated AVR with the Hancock II bioprosthesis (Medtronic,
Inc, Minneapolis, Minn). Four cohorts of this patient popula-
tion were constructed on the basis of the presence or absence
of CAD and age above or below 65 years at the time of oper-
ation: (1) younger than 65 years of age without CAD (n =
177), (2) younger than 65 years of age with CAD (n = 77), (3)
65 years of age or older without CAD (n = 196), and (4) 65
years of age or older with CAD (n = 220). 
All patients were entered prospectively into a hospital reg-
istry at the time of operation and were followed up prospec-
tively thereafter. Follow-up was conducted by either clinic
visit or telephone interview during a 4-month period that
ended in December 1996. When patients could not be con-
tacted via such methods, follow-up was obtained from a fam-
ily physician. All events were verified by physician letter.
To minimize transvalvular gradients, attempts were made
to match patient body surface area to bioprosthetic size with
the use of guidelines based on the hemodynamic performance
of the Hancock II bioprosthesis.8,9 To accomplish this, patch
enlargement of the aortic anulus was necessary in 19% of
patients undergoing AVR. In general, patch enlargement
enabled insertion of valves 1 to 2 sizes larger than would oth-
erwise be possible without enlargement.
From 1982 to 1989, all patients undergoing bioprosthetic
AVR at The Toronto Hospital were discharged from hospital
on a regimen of daily warfarin sodium for the first 3 months
after the operation. This practice was discontinued in 1990,
after which time patients received only aspirin (325 mg once
daily) after the operation.
Operative survivors underwent at least one echocardio-
graphic evaluation during the first postoperative year and
additional evaluations in the event of cardiac or valve-related
complications. Postoperative complications were prospec-
tively monitored and analyzed according to guidelines set
forth by The American Association for Thoracic Surgery.10
Outcomes. The primary outcome for this paper was to
define all causes of death. Cause of death was established
from hospital records or autopsy reports. We also evaluated
operative death, defined as any in-hospital death.
Bioprosthetic valve dysfunction was a secondary outcome.
Bioprosthetic valve dysfunction was defined as any clinically
relevant valvular stenosis or insufficiency documented by
Doppler echocardiography, reoperation, or autopsy. All 9
patients with valve dysfunction had primary tissue failure
(PTF) and underwent successful redo surgery within 1 to 9
weeks of the diagnosis of PTF. For the purpose of these
analyses, the date of operation was considered the failure date
for PTF. Because not all patients had undergone echocardio-
graphic evaluation by the time of the last follow-up contact,
the time to PTF may have been slightly over-estimated.
Additional outcomes included thromboembolic events (the
first event was included in analyses but not subsequent
events), bioprosthetic valve endocarditis, and repeat AVR.
Variables. The preoperative variables tested for their uni-
variate and multivariable association with the outcomes includ-
ed age, gender, New York Heart Association (NYHA) classifi-
cation, left ventricular grade (1, ejection fraction > 60%; 2,
ejection fraction 40%-60%; 3, ejection fraction 20%-39%; 4,
ejection fraction < 20%), preoperative echocardiographic
rhythm (sinus, atrial fibrillation/flutter, heart block), endo-
carditis, CAD, type of aortic valve lesion, and previous cardiac
operation. After a careful examination of the univariate results,
we collapsed 2 ordinal variables into dichotomous variables:
symptoms at rest (NYHA class IV vs NYHA classes I, II, or
III), and left ventricular dysfunction (left ventricular grades 3
and 4 vs left ventricular grades 1 and 2). As stated previously,
age was collapsed into a dichotomous variable, namely
younger than 65 years of age or 65 years of age and older. 
Statistical analyses. The SAS and BMDP programs (SAS
Institutes, Inc, Cary, NC; BMPD Software, Los Angeles,
Calif) were used for statistical analyses. Continuous variables
are presented as the mean ± standard deviation in the text and
as the mean ± standard error in tables and figures, unless oth-
erwise noted. 
Univariate. After a careful examination of the results of
univariate analyses and previously published reports, we
chose 65 years of age as a cut-off point for the construction
of 4 cohorts based on age and the presence or absence of
CAD. Differences in prognostic variables between the
cohorts were evaluated by analysis of variance for continuous
variables and c 2 or Fisher’s exact test for categoric variables.
Time-related data such as survival, freedom from throm-
boembolic events, freedom from reoperation, freedom from
PTF, or combined valve-related events were analyzed uni-
variately by the Kaplan-Meier (or product limit) test.
Multivariable. Operative death was analyzed multivariably
by logistic regression analysis. Late survival was evaluated
multivariably in the entire study population, by Cox regres-
sion analysis, and an accelerated time failure analysis by the
use of log-logistic regression. For both multivariable models
the same model-building strategy was used: those variables
that had a univariate P value < .25 or those of known biologic
274 Cohen et al The Journal of Thoracic and
Cardiovascular Surgery
February 1999
importance but failing to meet the critical alpha level were
submitted for consideration to the models by the use of step-
wise selection.
Regression coefficients from an accelerated time failure
model by the log-logistic distribution were used to calculate
the predicted probability of survival at specific time periods
from the formula:
S(t|X) = 1/1 + {e –g(b o + b 1X1.... + b nXn) · tg}
where S = survival probability, g = 1/scale, b = regression
coefficient, X = covariate, t = follow-up time (months). 
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Table I. Clinical characteristics of all patients by group
<65 y/no CAD <65 y/with CAD ‡ 65 y/no CAD ‡ 65 y/with CAD 
Characteristic (n=177) (n=77) (n = 196) (n = 220) P value
Follow-up (mo; mean ± SD) 82 ± 43 80 ± 43 67 ± 36 56 ± 35 .0001
Age (y; mean ± SD) 51 ± 11 59 ± 7 72 ± 5 73 ± 4 .0001
Gender (No.)
Male (%) 131 (74) 68 (88) 127 (65) 179 (81)
Female (%) 46 (26) 9 (12) 69 (35) 41 (19) .001
NYHA class (No.)
I (%) 15 (9) 0 3 (2) 1 (1)
II (%) 66 (37) 22 (29) 34 (17) 35 (16)
III (%) 55 (31) 33 (42) 98 (50) 100 (45)
IV (%) 41 (23) 22 (29) 61 (31) 84 (38) .001
Left ventricular grade (No.)
1. EF > 0.60 (%) 50 (34) 9 (14) 53 (32) 45 (23)
2. EF 0.40-0.60 (%) 69 (48) 33 (52) 73 (43) 96 (49)
3. EF 0.20-0.39 (%) 19 (13) 17 (27) 33 (20) 46 (23)
4. EF < 0.20 (%) 7 (5) 4 (6) 8 (5) 9 (5) .58
Rhythm before operation (No.)
Normal sinus rhythm (%) 170 (96) 74 (96) 167 (85) 188 (86)
Atrial fibrillation (%) 5 (3) 2 (3) 19 (10) 25 (11)
Complete heart block (%) 2 (1) 1 (1) 10 (5) 7 (3) .001
Endocarditis
Remote (%) 6 (3) 1 (1) 1 (0.5) 3 (1)
Active (%) 11 (6) 3 (4) 5 (3) 5 (3) .004
CAD 
Single vessel (%) — 17 (22) — 66 (30)
Double vessel (%) — 26 (34) — 73 (33)
Triple vessel (%) — 34 (44) — 81 (37) .001
Aortic valve lesion
Stenosis (%) 51 (29) 35 (45) 94 (48) 136 (62)
Insufficiency (%) 70 (39) 23 (30) 39 (20) 27 (12)
Mixed (%) 56 (32) 19 (25) 63 (32) 57 (26) .001
Previous cardiac operation (%)
Aortic valve repair (%) 7 (4) 0 0 0
AVR (%) 11 (6) 1 (1) 20 (10) 13 (6)
Mitral valve repair (%) 0 0 1 (0.5) 0
CABG (%) 1 (1) 4 (5) 3 (2) 12 (5) .001
Coronary artery bypass
One (%) — 16 (21) — 65 (30)
Two (%) — 21 (27) — 65 (30)
Three (%) — 26 (33) — 65 (30)
Four (%) — 13 (17) — 17 (8)
Five (%) — 1 (2) — 3 (2) .26
AVR-Hancock II 
21 mm (%) 6 (3) 4 (5) 20 (10) 18 (8)
23 mm (%) 29 (16) 16 (21) 75 (38) 78 (36)
25 mm (%) 49 (28) 22 (29) 54 (28) 83 (38)
27 mm (%) 71 (40) 29 (38) 38 (19) 36 (16)
29 mm (%) 22 (12) 6 (8) 9 (5) 5 (2) .001
Patch enlargement (%) 37 (21) 9 (12) 38 (19) 41 (19) .373
Crossclamp time (min) 64 ± 25 81 ± 23 62 ± 24 87 ± 24 .0001
Cardiopulmonary bypass time (min) 86 ± 33 108 ± 32 84 ± 20 120 ± 34 .0001
EF, Ejection fraction.
Results
Patients and follow-up. Table I summarizes the clin-
ical and operative data of all patients by cohort.
Although the 670 operative procedures were divided
among 11 surgeons, 2 surgeons performed almost three
fourths of the operations (493 AVRs; 74%). Patients
with significant CAD on preoperative angiography
underwent a concomitant coronary artery bypass graft
operation (CABG). Twenty-seven percent of patients
underwent previous AVR or repair; 13% of patients
underwent previous CABG.
Follow-up of all patients was 99.7% complete at a
mean follow-up time of 69 ± 40 months (median, 66
months; range, 0.1-168 months), with 75% of patients
providing follow-up of at least 93 months. Two patients
were lost to follow-up, both of whom were younger
than 65 years of age and only one of whom had con-
comitant CAD. Mean patient age was 65 ± 12 years
(median, 68 years; range, 18-86 years). Mean body sur-
276 Cohen et al The Journal of Thoracic and
Cardiovascular Surgery
February 1999
Table II. Operative death and morbidity
<65 y/no CAD <65 y/with CAD ‡ 65 y/no CAD ‡ 65 y/with CAD 
Characteristic (No.) (n = 177) (n = 77) (n = 96) (n = 220) P value
Hospital deaths (%) 6 (3) 5 (7) 5 (3) 16 (7) .165
Early reoperation
Bleed (%) 8 (5) 4 (5) 10 (5) 16 (7)
Tamponade (%) 0 0 1 (0.5) 4 (2)
Arrest (%) 0 0 0 1 (0.5)
Sternal infection (%) 0 0 0 3(1)
Sternal dehiscence (%) 1 (0.5) 0 0 1 (0.5)
Other (%) 1 (0.5) 0 0 1 (0.5) .067
Perioperative MI (%) 4 (2) 1 (1) 2 (1) 2 (1) .238
Postoperative pacing* (%) 8 (5) 1 (1) 13 (7) 19 (9) .042
Stroke (%) 3 (2) 0 5 (3) 14 (6) .006
Sternal infection (%) 0 1 (1) 1 (0.5) 7 (3) .012
Other wound infection (%) 1 (0.5) 0 2 (1) 3 (1) .317
MI, Myocardial infarction.
*Postoperative permanent pacemaker requirement.
Table III. Late death and morbidity
<65 y/no CAD <65 y/with CAD ‡ 65 y/no CAD ‡ 65 y/with CAD 
Characteristic (No.) (n = 177) (n = 77) (n = 196) (n = 220)
Late deaths* (%) 25 (14) 17 (22) 42 (21) 62 (28)
Causes of late death (%)
Valve-related deaths† (%) 5 (3) 0 5 (3) 7 (3)
Cardiac (nonvalve related)‡ (%) 10 (6) 8 (11) 19 (10) 22 (10)
Noncardiac/nonvalve (%) 10 (6) 9 (12) 18 (9) 33 (15)
PTF (%) 5 (3) 4 (5) 0 0
Thromboembolism (%)
New stroke (%) 2 (1) 1 (1) 14 (7) 14 (6)
New TIA (%) 4 (2) 2 (3) 4 (2) 5 (2)
Reoperation at follow-up (%) 12 (7) 4 (5) 2 (1) 4 (2)
Prosthetic valve endocarditis (%) 7 (4) 0 4 (2) 6 (3)
Valve-related morbidity§ (%) 22 (12) 8 (10) 22 (11) 27 (12)
Valve-related M+MII(%) 48 (27) 29 (38) 58 (30) 95 (43)
*All deaths, excluding hospital deaths. 
†Death from valve failure, cerebrovascular event, or prosthetic valve endocarditis. 
‡Death from ischemic heart disease, congestive heart failure, or sudden death. 
§Morbidity caused by new stroke, new TIA, reoperation for valve failure, and prosthetic valve endocarditis. 
IIMorbidity or death from valve-related factors.
Table IV. Cox regression model for survival
Regression 
Variable coefficient ± SE Risk ratio
CAD 0.4297 ± 0.158 1.54
Age ± 65 years 0.5383 ± 0.171 1.71
Left ventricular dysfunction 0.3981 ± 0.173 1.49
(grades 3 and 4)
Symptoms at rest 0.5851 ± 0.160 1.80
(NYHA, grade 4)
Male gender 0.3719 ± 0.199 1.45
face area was 1.81 ± 0.29 m2 (median, 1.84 m2; range,
1.5-2.6 m2). Age and duration of follow-up by group
are presented in Table I.
Operative mortality and morbidity. Table II shows
the operative mortality and morbidity rates in all
patients by group. All but 6 patients with CAD on pre-
operative angiogram underwent concomitant CABG.
Among these 6 patients who did not undergo revascu-
larization, 3 patients were alive at late follow-up, and 3
patients died at a mean of 41 ± 9 months after having
survived their initial operation. Logistic regression
analysis revealed both CAD (odds ratio, 2.1; 95% con-
fidence interval [CI], 0.9-4.8) and advanced NYHA
functional class IV (odds ratio, 3.1; 95% CI, 1.4-6.9) to
be associated with an increased risk of operative death. 
Late death and morbidity. A summary of the caus-
es of late death and morbid events is shown in Table III.
There were 146 late deaths (22%). The first Cox propor-
tional hazard analysis of the entire data set revealed
that active endocarditis, age 65 years or more, NYHA
class IV, left ventricular grades 3 or 4, the presence of
CAD, and male gender were predictive of late death.
However, all deaths secondary to active endocarditis
occurred during the early postoperative period; and be-
cause of the small number of patients with active endo-
carditis, this variable was excluded from subsequent
multivariable analyses. After controlling for gender, the
independent predictors of late survival by Cox regression
were the presence of CAD, age (‡ 65 years), left ven-
tricular dysfunction, and symptoms at rest (Table IV).
The global c 2 for this analysis was 63.78, P < .0001.
The regression coefficients ± standard errors and P
values for the accelerated time failure model with the
use of the log-logistic distribution are given as follows:
intercept (7.3346 ± 0.395; P = .0001), presence of
CAD (–0.7485 ± 0.3138; P = .0171), age of 65 years or
older (–0.6192 ± 0.3387; P = .0675), NYHA functional
class IV (–0.718 ± 0.3289; P = .029), and left ventric-
ular dysfunction (–0.8666 ± 0.3336; P = .0094). The
scale factor was 1.5457 ± 0.121. Table V shows the pre-
dicted probability of survival at 5 and 10 years, calcu-
lated by the log-logistic model for combinations of
dichotomized risk factors.
The actuarial survival for all patients was 54% ± 4%
at 12 years (62% ± 9% in female patients and 51% ±
5% in male patients; P = .017). Figs 1, 2, 3, and 4
demonstrate the effect of age, functional class, left ven-
tricular function, and CAD, respectively, on long-term
survival. The combined effect of age and CAD on
patient survival is shown in Fig 5. 
PTF. Bioprosthetic valve dysfunction caused by PTF
occurred in 9 patients, all of whom were younger than
65 years of age (<65 years of age without CAD, 5
patients; <65 years of age with CAD, 4 patients; Table
III). The mean time to reoperation for the valves that
failed was 87 ± 28 months (7.25 years; median, 87.5
months; range, 37-122 months). All patients with PTF
underwent successful reoperations within 9 weeks of
diagnosis of valve dysfunction. As seen in Fig 6, there
was no PTF in patients who were 65 years of age or
older, regardless of CAD status. 
Thromboembolic events. There were a total of 46
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Table V. Survival probability calculated from the accelerated time failure model with the log-logistic distribution
for combinations of risk factors
NYHA Left ventricular Predicted survival Predicted survival 
CAD Age ‡ 65 y grade IV grades 3 or 4 at 5 y (%) at 10 y (%)
89.1 (73, 100) 83.9 (73, 95)
3 83.4 (70, 97) 76.2 (67, 85)
3 84.5 (71, 98) 77.7 (69, 86)
3 83.6 (70, 97) 76.6 (68, 85)
3 82.3 (69, 96) 74.8 (66, 84)
3 3 77.1 (66, 88) 68.2 (61, 75)
3 3 75.9 (65, 87) 66.8 (60, 74)
3 3 74.1 (63, 85) 64.6 (58, 72)
3 3 77.4 (66, 88) 68.6 (62, 76)
3 3 75.7 (65, 86) 66.5 (59, 74)
3 3 74.5 (64, 85) 65.1 (58, 72)
3 3 3 67.8 (59, 77) 57.4 (52, 63)
3 3 3 65.7 (57, 75) 55.0 (49, 61)
3 3 3 66.2 (57, 75) 55.5 (50, 61)
3 3 3 3 54.6 (47, 62) 43.5 (39, 48)
Each of these 4 risk factors was entered into the model as a dichotomous variable (ie, NYHA IV versus NYHA I, II, or III; left ventricular grades 3 or 4 versus left
ventricular grades 1 or 2). The check mark ( 3 ) indicates the risk factor is present. These 4 risk factors are not present for the first row of estimates. The upper and
lower 95% CI for the predicted survival probabilities are given in parentheses. 
late thromboembolic events (32 strokes; 14 transient
ischemic attacks [TIAs]), all of which represented pri-
mary events. Seven of the strokes were fatal (< 65 years
of age without CAD, 1 patient; <65 years of age with
CAD, 0 patients; ‡ 65 years of age without CAD, 3
patients; ‡ 65 years of age with CAD, 3 patients). The
actuarial freedom from thromboembolic events at 12
years was 94% ± 2% in patients who were younger
than 65 years of age without CAD, 93% ± 3% in
patients who were younger than 65 years of age with
CAD, 82% ± 5% in patients who were 65 years of age
or older without CAD, and 64% ± 13% in patients who
were 65 years of age or older with CAD (P = .0127).
Cox regression analysis revealed that age 65 years or
older and the presence of concomitant CAD were asso-
ciated with an increased incidence of thromboembolic
complications. The absence of aspirin was also associ-
ated with an increased incidence of thromboembolic
events, although information regarding aspirin use was
incomplete. 
Bioprosthetic valve endocarditis. Bioprosthetic
valve endocarditis developed in 17 patients (<65 years
278 Cohen et al The Journal of Thoracic and
Cardiovascular Surgery
February 1999
Fig 1. Influence of age on late survival after AVR: Actuarial survival was significantly decreased for patients who
were 65 years of age or older in comparison with patients who were younger than 65 years of age, irrespective
of CAD status (P < .001).
Fig 2. Influence of preoperative NYHA class on late survival after AVR: Patients in NYHA classes I to III before
the operation demonstrated the best long-term survival, and patients in NYHA class IV demonstrated the poorest
long-term survival (P < .0001).
of age without CAD, 7 patients; <65 years of age with
CAD, 0 patients; ‡ 65 years of age without CAD, 4
patients; ‡ 65 years of age with CAD, 6 patients).
Antibiotic therapy along with reoperation was under-
taken in 7 of these patients, all of whom survived. The
remaining 10 patients, none of whom survived, received
antibiotic therapy only. The actuarial freedom from
endocarditis at 12 years was 93% ± 2% in patients who
were younger than 65 years of age without CAD, 99%
± 1% in patients who were younger than 65 years of age
with CAD, 98% ± 1% in patients who were 65 years of
age or older without CAD, and 83% ± 13% in patients
who were 65 years of age or older with CAD (P = .543). 
Repeat AVR. Twenty-two patients were found to
have undergone repeat AVR at the time of follow-up
(Table III). The rate of reoperation was significantly
higher in the younger age group (<65 years of age),
irrespective of CAD status. The indications for reoper-
ation included aortic dissection (1 patient), increased
left ventricular outflow tract gradient with a normally
functioning valve (1 patient), periprosthetic leakage (3
patients), PTF (9 patients), prosthetic valve endocardi-
tis (7 patients), and recurrent TIA (1 patient). Only one
patient undergoing reoperation for periprosthetic leak-
age died during the operation. The actuarial freedom
from reoperation at 12 years was 82% ± 6% in patients
who were younger than 65 years of age without CAD,
88% ± 6% in patients who were younger than 65 years
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Fig 3. Influence of preoperative left ventricular grade on late survival after AVR: Actuarial survival was signifi-
cantly decreased for patients with preoperative left ventricular grades 3 or 4 in comparison with patients with left
ventricular grades 1 or 2 (P < .0001).
Fig 4. Influence of CAD on late survival after AVR: Actuarial survival was significantly decreased for patients
with CAD in comparison with patients without CAD, irrespective of age (P < .0001).
of age with CAD, 99% ± 1% in patients who were 65
years of age or older without CAD, and 98% ± 1% in
patients who were 65 years of age or older with CAD
(P = .045). Cox regression analysis revealed only age
65 years or younger to be predictive of reoperation (risk
ratio, 2.9; 95% CI, 1.1-7.5). 
Discussion
It remains difficult to match the patient requiring
AVR to the appropriate prosthetic heart valve. Mechan-
ical valves are more durable than bioprosthetic valves
but necessitate permanent oral anticoagulation and are
associated with a constant risk of bleeding and throm-
boembolic complications.11,12 Bioprosthetic heart
valves are less thrombogenic than mechanical valves
and do not require oral anticoagulation. However,
because of limited durability, reoperation may be nec-
essary in patients who outlive the valves.12 Thus in
addition to considering patient preference and their
ability to take oral anticoagulants, surgeons must aim
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Fig 5. Combined influence of age and CAD on late survival after AVR: Patients who were younger than 65 years
of age with no CAD demonstrated the best long-term survival, patients who were younger than 65 years of age
with CAD or patients who were 65 years of age or older without CAD demonstrated intermediate long-term sur-
vival, and patients who were 65 years of age or older with CAD demonstrated the poorest long-term survival (P
< .0001).
Fig 6. Combined influence of age and CAD on freedom from PTF after AVR: Actuarial freedom from PTF was
significantly decreased for patients who were younger than 65 years of age in comparison with patients who were
65 years of age or older, irrespective of CAD status (P = .0255).
to optimize the quality of life and minimize the risk of
death and morbidity when counseling their patients
who require AVR. 
This study was designed to evaluate factors that may
affect long-term survival after AVR with the Hancock
II bioprosthesis, a heart valve that has been used at our
institution since 1982.8,13 We also analyzed the risk of
valve-related complications in this population. 
After careful analysis of our data, we found the fol-
lowing preoperative cardiac comorbid conditions to be
associated with increased risk of late death after AVR:
symptoms at rest (risk ratio, 1.80), age 65 years or
older (risk ratio, 1.71), CAD (risk ratio, 1.54), left ven-
tricular ejection fraction less than 40% (risk ratio,
1.49), and male gender (risk ratio, 1.45). Age was the
only factor that affected bioprosthetic durability in this
study. There were no cases of PTF at 12 years in
patients older than 65 years of age. Age 65 years or
older and CAD were associated with a higher risk of
thromboembolic complications.
Although age was not an independent predictor of
operative death in our study, it had a significant effect
on late death as shown in Fig 1 and in previous stud-
ies.4-6,14-16 Male gender was similarly found to have a
negative effect on long-term survival, an observation
previously described by He and colleagues.15
Advanced functional status (NYHA functional class
IV) has been identified as an important prognostic vari-
able for operative death in numerous studies.3,5,11,14
Our study demonstrates an increased risk of death after
the operation in this patient sample. In fact, NYHA
class IV was the most powerful predictor of death after
AVR in our series, as shown in Fig 2.
Left ventricular function has also been identified as a
risk factor for death both early and late after AVR.4 In
our series, there was a significant difference in 12-year
survival for patients with ejection fractions below 40%
versus those with ejection fractions above 40%, as
shown in Fig 3. 
The presence of CAD at the time of operation was
found to have an independent effect on late death (Fig
4). At 12 years, the best overall survival was demon-
strated by younger patients without CAD, and the
worst survival was in older patients with CAD (Fig 5).
Younger patients with CAD and older patients without
CAD demonstrated similar survival after AVR. Several
studies have similarly documented the adverse effect of
CAD in AVR.6,14,16 In a review by Jones and col-
leagues,6 which included both mechanical and prosthet-
ic valves, age and CAD were shown to have a signifi-
cant impact on both early and late patient survival after
AVR. The 10-year actuarial survival after AVR was
60% in patients without CAD and 39% in those with
CAD. The negative effect of CAD was evident in every
age group.6
Late survival after AVR was dependent on multiple
factors in our series. Because none of these factors
should be viewed in isolation, we estimated the 5- and
10-year actuarial survival using a log-logistic model
shown in Table V. Thus the predicted 10-year survival
after AVR ranged from approximately 84% (patients
who were younger than 65 years of age without any
cardiac comorbid conditions) to 43% (patients who
were 65 years of age or older with CAD, NYHA class
IV, and left ventricular ejection fraction below 40%).
We provide Table V as an interesting tool that may be
useful to estimate patient survival by the probability of
bioprosthetic valve failure. 
PTF represents the major limitation to bioprosthetic
heart valves. Age and valve position have been shown
to be important determinants of valve longevity with
increased prosthetic durability in the aortic position
and in older patients where hemodynamic stresses may
be minimized.17-19 Burr and colleagues19 found that
freedom from PTF after AVR with the Carpentier-
Edwards porcine bioprosthesis was 98% for patients 65
to 69 years of age at 15 years after implantation, 95%
for patients 70 to 79 years of age at 13 years after
implantation, and 100% for patients 80 years of age or
older at 13 years after implantation.
In the current study, only 9 cases of PTF were demon-
strated, all of which occurred in patients younger than
65 years of age. Thus freedom from PTF in patients 65
years of age or older was 100% at 12 years. 
Although our study suggested a number of predictors
for late outcome, the inherent limitations are those that
apply to any observational outcomes analysis. The pos-
sibility of significant residual and unmeasured con-
founding variables remains a concern. Moreover, the
generalizability of the regression model is threatened
by both patient selection and a relatively small sample
size with small numbers of events. It is likely that sev-
eral more independent predictors of survival could
have been identified with a larger sample size and/or
more adverse events. These results merely illustrate the
continued dilemma faced by cardiac surgeons in their
attempt to select the most appropriate valvular prosthe-
sis for AVR on the basis of predictors of outcome.
Conclusions
Long-term survival after AVR with a bioprosthetic
valve is highly dependent on premorbid conditions
such as age, ventricular function, CAD, and functional
class, none of which should be viewed in isolation. By
analyzing the combined effects of these important vari-
ables on patient outcome and bioprosthetic valve dura-
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bility, guidelines for valve selection can be successfully
formulated in most cases. In consideration of these fac-
tors, we have developed the following inferences re-
garding the use of bioprosthetic valves for AVR:
Age younger than 65 years without CAD: Patient sur-
vival is likely to exceed tissue valve durability. Thus
reoperations for PTF will likely become necessary.
Age younger than 65 years with CAD: The negative
impact of age on bioprosthetic durability in the younger
aged groups was far more significant than the negative
impact of CAD on survival in the same groups. Thus
reoperation as the result of PTF must also be consid-
ered in such patients.
Age 65 years or older without CAD: Although sur-
vival in patients who are older than 65 years of age
without CAD was similar to that of patients who were
younger than 65 years of age with CAD, bioprosthetic
valves were more durable in this age group. Thus
patients who are 65 years of age or older without CAD
are less likely to outlive their bioprosthetic valves. 
Age 65 years or older with CAD: The markedly
decreased survival in patients who are 65 years of age
or older with CAD, along with the age-related increase
in tissue valve durability may make a bioprosthesis
ideal in such patient subgroups.
NYHA class IV or left ventricular grades 3,4:
Because of the markedly decreased life expectancy, bio-
prosthetic valves may be appropriate for these patients.
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Discussion
Dr Robert W. Emery (Minneapolis, Minn). This paper
reviews a 12-year retrospective experience with the Hancock
II porcine bioprosthesis. After an elegant statistical review, an
algorithm for the use of this prosthesis based on significant
comorbid factors affecting long-term death is constructed, as
you have just seen. In addition, many lessons are between the
lines. Combinations of risk factors are particularly relevant in
the prediction of long-term survival, as Dr Cohen has shown.
Perioperative morbidity is clearly increased in the older age
groups. The absence of aspirin was associated with an
increased risk for thromboembolic events. And patients hav-
ing prosthetic valve endocarditis did not survive in the
absence of surgical therapy. 
In reviewing the data, several other facts can be construed,
and the conclusions, particularly related to the older age
groups, questioned. The mean follow-up time of the series
was 69 months and the median survival was 66 months in the
older age group patients with CAD. However, the mean time
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of valve failure in the overall group was 87 months. In fact,
the follow-up in the highest risk group, those patients over 65
years with coronary disease, was 56 months. After 6 years the
number of patients at risk was small. Could these facts alter
the algorithms suggested? 
Coronary disease is a known negative determinant of long-
term survival. The details of bypass grafting in this presenta-
tion were not ascertained. At the 1997 Society of Thoracic
Surgeons (STS) meeting our group presented the results of a
15-year series of patients, having isolated AVR with a
mechanical valve prosthesis as compared with those having
AVR with the same prosthesis but having coronary bypass
grafting. Similar to the current report, the actuarial survival
curves split significantly at 6 months and remained different
throughout the period reviewed, with the patients with coro-
nary disease having poor survival. However, when the inter-
nal thoracic artery was used as a portion of the bypass proce-
dure, the survival of patients having AVR with and without
CAD was equivalent; that is, the use of the thoracic artery as
part or the complete bypass operation, as opposed to saphe-
nous veins alone with the concomitant AVR, improved the
survival of those with coronary disease to the level of patients
with valve replacement alone, extending over a 12-year fol-
low-up period. This was not age dependent because the
patient group over and under 70 years were both returned to
the respective survival curves of similar patients having AVR
who did not have CAD. Was the use of the internal thoracic
artery as a conduit in construction of the bypass grafts evalu-
ated in your data at all? 
Additionally, the need for outflow tract enlargement was
19% overall. And in the older age group, the same. In the
series of over 1500 mechanical valves mentioned, the perfor-
mance of annular enlargement procedures was less than 1%.
Because the older patients are at increased risk for long-term
morbidity and death, do you think the completion of a more
complicated procedure in this higher risk group had any con-
tribution to the overall long-term impact of increased mor-
bidity and death? 
The freedom from thromboembolic events was seemingly
low, especially in the elderly patients. Freedom from throm-
boembolic events at 12 years in patients having internal tho-
racic artery versus those having saphenous vein graft, in the
report we made at the STS meeting, was improved, 99% ver-
sus 95%, respectively. Did the addition of outflow tract
reconstruction or the use of the internal thoracic artery (ITA)
impact morbid long-term event rate? 
Finally, the Toronto group has pioneered the use of stent-
less valves and reported excellent long-term freedom from
PTF and excellent gradient relief. Does the approval and
more common use of this valve modify the algorithm? 
Dr Cohen. With regards to your comments on AVR with
left internal thoracic artery (LITA), I was actually fortunate
enough to have seen your data before. Although our data
involve only tissue valves, I think that our results are some-
what generalizable to your results because none of the deaths
in this group, or very few of these deaths, were valve related.
I can also say that we have been using the LITA since 1984
regularly and that most of these patients, if not all of them,
would have received an LITA. 
Now, with respect to AVR revascularization, we found that
patients with CAD had a poorer survival despite revascular-
ization. And this isn’t really all that surprising because CABG
is really only a palliative procedure. I think that although your
results are quite impressive, it may be difficult to generate any
definitive conclusions because of the short follow-up period
and the fact that there are relatively few numbers of patients in
your cohort in the late time periods of follow-up. If you were
to extend your follow-up period to 12 years or so, you may
begin to see that the curves, the 2 curves, cross. Namely, for
patients undergoing AVR with LITA, the curve starts to come
down and the survival starts to come closer to patients in our
group who had CAD with AVR. 
The other thing I would like to say is that, obviously (and I
know, Dr Emery, that your group puts in a lot of mechanical
valves) if you can avoid reoperation by putting in a mechan-
ical prosthesis, then by all means this should be your main
objective. But I would not do so at any cost, because the risk
of bleeding complications, especially in elderly patients, is
quite high, in some series as high as 68%. In that case, if a
mechanical valve can be avoided, then it should. That is all I
will say about mechanical valves. 
With respect to your question about annular enlargement.
Interestingly enough, we actually looked this up recently at
the Toronto Hospital, and we compared patients who under-
went annular enlargement with patients who were left with
just a small prosthesis. What we found was quite interesting
in that the functional status was improved; however, survival
was not improved. Now, these are only preliminary results,
such that I do not believe that the presence of patch enlarge-
ment, in our patients anyway, skewed our data in any way.
But obviously, we will have to look into this further. 
With respect to the high thromboembolic rate, you are cor-
rect in saying that there was a relatively low thromboembolic
rate. We used to have a higher thromboembolic rate. What we
used to do is discharge our patients with bioprostheses receiv-
ing warfarin (Coumadin) therapy only for 3 months, after
which time they would not be receiving any anticoagulant
therapy. Now, we keep them on warfarin therapy for 3 months
and at discharge prescribe aspirin therapy. We seem to have
seen a decrease in the event rate as far as thromboembolism
is concerned in these patients. 
And finally, with regard to your question about the
Toronto SPV valve (St Jude Medical, Inc, St Paul, Minn),
and I hope I do Dr David proud here, we have seen quite
good results with our Toronto SPV valves. Dr David has
recently reviewed our results. At 8 years postoperatively, our
actuarial survival was 91% in SPVs when we compared
them with a similar group of patients who received a
Hancock II bioprosthesis. Freedom from cardiac-related
deaths was 95% in Toronto SPV valves and 81% in Hancock
II valves. Freedom from valve-related death, however, was
similar in the two groups. 
Now, we have recently reviewed the incidence of PTF in
these same patients with Toronto SPV valves, and we found a
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trend toward PTF at about the same time that the Hancock II
patients would start to experience PTF. So, although Toronto
SPV valve may confer a survival benefit, I am not sure that it
confers a benefit with respect to a PTF or increased durability.
Dr Manuel J. Irarrazaval (Santiago, Chile). Just one
question. Dr David always is very strong on enlarging the
anulus to avoid the gradient. I think it is reflected here in your
19% incidence of enlargement. Could you tell us something
about the long-term survival results according to valve size
and regression of left ventricular hypertrophy. Could you find
some relationship there to justify this enlargement or is it bad
news to leave a small anulus?
Dr Cohen. I think it would be premature to make any con-
clusions with respect to left ventricular mass regression. An
earlier study of ours seemed to suggest that there is greater
mass regression, and mass regression is achieved earlier in
patients receiving the Toronto SPV valve. Now, unfortunately,
those groups of patients were highly selected. We are cur-
rently undertaking a prospective, randomized trial where we
are randomizing patients to either a Carpentier-Edwards or a
Toronto SPV valve and comparing mass regression in these
patients. Whether or not this is the reason for the improved
survival in patients receiving the SPV valve, I cannot com-
ment at this point, but that definitely could be a possibility.
Dr Bruce W. Lytle (Cleveland, Ohio). Dr Emery asked
about the use of ITA grafts. If I understood your answer cor-
rectly, you said that you had used those grafts since 1984. I
would then interpret that to mean that most of these patients
had ITA grafts; is that correct?
Dr Cohen. Yes.
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